南韓與輝瑞及Moderna談判生產10億劑新冠疫苗
《路透》報道,南韓政府正與輝瑞(PFE.US)及Moderna(MRNA.US)在內的mRNA疫苗製造商進行談判,希望能立即生產多達10億劑疫苗。
較早時南韓已經與阿斯利康及俄羅斯在當地生產3種新冠疫苗達成協議,同時還與Moderna簽訂疫苗的包裝協議。
南韓當局表示,一直與大型藥廠就生產mRNA疫苗進行頻繁的討論,但未有透露可以立即投產的南韓疫苗製造商,不過據悉包括Hanmi Pharmaceuticals及Quratis。Hanmi表示,此前爲藥廠賽諾菲的糖尿病藥物預留大量產能,但由於該藥物的研發工作停滯不前,可以將產能用於生產疫苗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.